Secondary glioblastoma multiforme – local alpha emitters targeted therapy with 213Bi-DOTA-substance P

Glioblastoma multiforme (GBM) is the most common and malignant primary brain tumor. GBM may be primary or secondary. Primary GBM develop rapidly in elderly patients without histologic evidence of less malignant precursor lesions. Secondary GBM progress from low-grade diffuse astrocytoma or anaplastic astrocytoma. They manifest in younger patients. Histologically, primary and secondary GBM are largely indistinguishable, but they differ in their genetic and epigenetic profiles. Secondary GBM account for about 9% of all GBM. The median overall survival time in untreated patients with secondary GBM is 7.8 months, and in patients after surgery and radiotherapy - 27.1 months. Advancements in the past decades have not significantly increased the overall survival of patients with this disease. GBM has been demonstrated NK-1 receptor system and substance P can be used as a ligand for targeted therapy. Alpha emitters like 213Bi offer the new potential for selective irradiation of tumors, with minimizing damage to adjacent tissue.

KROLICKI Leszek;  MORGENSTERN Alfred;  KUNIKOWSKA Jolanta;  KOZIARA H;  KROLICKI B;  JAKUCINSKI M;  PAWLAK Dariusz;  APOSTOLIDIS Christos;  BRUCHERTSEIFER Frank; 

2016-12-01

SPRINGER

JRC101454

1619-7070,   

https://publications.jrc.ec.europa.eu/repository/handle/JRC101454,   

10.1007/s00259-016-3484-4,